

VPA10988/096/001

Milpro 4 mg/10 mg film-coated tablets for small cats and kittens

Variation	Summary	Date
Vet - C10 a)	VNRA - Vet - C10 a) - - Vet - C10 a) - Changes to the labelling or the package leaflet which shall not be connected with the SPC: administrative information concerning the holder's representative	28/08/25
Vet - B44 a)	VNRA - Vet - B44 a) - - Vet - B44 a) - Submission of a Ph. Eur. CEP for:— active substance;— starting material, reagent or intermediate used in the manufacturing process of the active substance;— excipient - Updated certificate	22/08/25
Vet - B44 b)	VNRA - Vet - B44 b) - - Vet - B44 b) - Submission of a Ph. Eur. CEP for:— active substance;— starting material, reagent or intermediate used in the manufacturing process of the active substance; — excipient - New certificate	22/08/25
Vet - G.I.18	VRA-S - Vet - G.I.18 - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004 - G.I.18 Safety, Efficacy, Pharmacovigilance changes - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004	17/07/25
Vet - C6	VNRA - Vet - C6 - Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17 - C6 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17	03/06/25
Vet - F.III.1 a) z.	VRA-R - Vet - F.III.1 a) z. - a) European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph. z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.III.1 a) z. Quality Changes - CEP/TSE/MONOGRAPHS -Submission of a new or updated Ph. Eur. certificate of suitability or deletion of Ph. Eur. certificate of suitability: -For an active substance -For a starting material/reagent/intermediate used in the manufacturing process of the active substance -For an excipient European Pharmacopoeial Certificate of Suitability to the	06/01/25

	relevant Ph. Eur. Monograph - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	
Vet - F.III.1 a) z.	VRA-R - Vet - F.III.1 a) z. - a) European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph. z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.III.1 a) z. Quality Changes - CEP/TSE/MONOGRAPHS -Submission of a new or updated Ph. Eur. certificate of suitability or deletion of Ph. Eur. certificate of suitability: -For an active substance -For a starting material/reagent/intermediate used in the manufacturing process of the active substance -For an excipient European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	06/01/25
Vet - F.III.1 a) z.	VRA-R - Vet - F.III.1 a) z. - a) European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph. z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.III.1 a) z. Quality Changes - CEP/TSE/MONOGRAPHS -Submission of a new or updated Ph. Eur. certificate of suitability or deletion of Ph. Eur. certificate of suitability: -For an active substance -For a starting material/reagent/intermediate used in the manufacturing process of the active substance -For an excipient European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	06/01/25
Vet - F.III.1 a) z.	VRA-R - Vet - F.III.1 a) z. - a) European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph. z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.III.1 a) z. Quality Changes - CEP/TSE/MONOGRAPHS -Submission of a new or updated Ph. Eur. certificate of suitability or deletion of Ph. Eur. certificate of suitability: -For an active substance -For a starting material/reagent/intermediate used in the manufacturing process of the active substance -For an excipient European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	06/01/25
Vet - B3 i)	VNRA - Vet - B3 i) - i) Deletion of a component or components of the flavouring or colouring system - B3 i) Changes to the quality part of the dossier: Deletion of a component or components of the flavouring or colouring system	21/10/24
Vet - F.II.c.1 z)	VRA-R - Vet - F.II.c.1 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.II.c.1 z) Quality Changes - Finished Product -Control of excipients-Change in the	09/12/22

	specification parameters and/or limits of an excipient - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	
Vet - F.II.c.4 z)	VRA-R - Vet - F.II.c.4 z) - z) Other changes under this code level e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021 - F.II.c.4 z) Quality Changes - Finished Product -Control of excipients-Change in synthesis or recovery of a non- pharmacopoeial excipient (when described in the dossier) or a novel excipient - Other changes under this code level, e.g. variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	09/12/22